FS03.6Efficacy of MAS063D (''Atopiclair'') in irritant contact dermatitis

Objective:  To determine the efficacy of a topical, MAS063D, in managing the clinical signs and symptoms of experimentally induced irritant contact dermatitis (ICD).
Methods:  Two patches of ICD were created using sodium lauryl sulfate (SLS) in 20 consenting volunteers. MAS063D was applied to one patch and a vehicle‐only control to the other. Measurements were taken at baseline, 24, 48 and 72 hours as follows: blood flow volume (BFV); skin color (a*); transepidermal water loss (TEWL); patient's view of itch and visual scoring. Results: The objective measurements of BFV, a* and TEWL all showed statistically significant benefits of MAS063D over the vehicle‐only control. BFV and a* were significantly better at all time points (p = 0.046, p = 0.045 respectively at 72 hours) and TEWL at 48 and 72 hours (p = 0.02 at 72 hours). MAS063D demonstrated benefit in the visual scoring of irritant contact dermatitis that was not statistically significant. Patient‐assessed itch was low at baseline; significant improvement was neither expected nor demonstrated although a small benefit of MAS063D over vehicle was seen in the mean values.
Conclusions:  BFV and a* are both good indicators of local erythema. TEWL is a good indicator of skin integrity. MAS063D therefore demonstrated statistically significant benefit over vehicle on three clinically meaningful outcomes of SLS‐induced ICD, and therefore may benefit irritant contact dermatitis.